Shares of Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.67.
A number of analysts have weighed in on MGX shares. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright raised their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th.
Check Out Our Latest Analysis on MGX
Hedge Funds Weigh In On Metagenomi
Metagenomi Stock Performance
Shares of Metagenomi stock opened at $2.36 on Tuesday. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.50. The company’s 50 day moving average price is $3.01 and its two-hundred day moving average price is $2.64.
Metagenomi Company Profile
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Read More
- Five stocks we like better than Metagenomi
- How to Invest in Biotech Stocks
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- DuPont’s Electronics Spinoff: The Start of Something Big
- Expert Stock Trading Psychology Tips
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.